Group 1 - The company announced the convening of the eighth employee representative assembly on November 12, 2025 [2] - During the assembly, employees voted to remove Mr. Chen Jinkang from his position as employee supervisor [2] - Ms. Chen Liyue was elected as the employee representative director for the company's eighth board of directors [2]

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical, Hua Xuande, has transferred his shares to his daughters, resulting in a change in the company's control structure, primarily due to Hua's advanced age [2][3][4]. Share Transfer Details - Hua Xuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, Hua Lirong and Hua Xiaohui [3][4]. - After the transfer, Hua Lirong holds 22.17% of Jiuzhou Pharmaceutical directly and indirectly, while Hua Xiaohui holds 13.36% indirectly [2][3]. Financial Aspects - The total value of the shares transferred from Zhongbei Group was 61.115 million yuan, and the shares from Taizhou Gede were valued at 700,000 yuan [4]. Background Information - Hua Xuande, born in 1943, is 82 years old and has gradually stepped back from management roles in Jiuzhou Pharmaceutical over recent years [5][9]. - The company was founded focusing on the research, production, and sales of chemical raw materials and pharmaceutical intermediates, later transitioning to contract custom development and production [9]. Control Structure Post-Transfer - Following the transfer, the actual controllers of Jiuzhou Pharmaceutical are now Hua Lirong and Hua Xiaohui, with Zhongbei Group remaining the controlling shareholder [4][8].

Core Points - The company announced the convening of the 18th meeting of the 8th Board of Directors on November 12, 2025 [1] - During the meeting, Hua Lirong was elected as the director representing the company to execute company affairs [1] - Hua Lirong will also serve as the legal representative of the company, with a term lasting until the end of the current Board's term [1]

证券代码：603456 证券简称：九洲药业 公告编号：2025-066 二、选举职工代表董事情况 根据《中华人民共和国公司法》及《公司章程》等相关规定，公司于 2025 年 11 月 12 日召开第八届职工代表大会，经与会职工讨论并投票表决，同意免去 陈锦康先生的职工监事职务，并选举陈丽月女士（简历附后）为公司第八届董事 会职工代表董事，任期自本次公司职工代表大会选举通过之日起至公司第八届董 事会任期届满之日止。 陈丽月女士符合相关法律法规、规范性文件及《公司章程》有关董事任职的 资格和条件。本次选举职工代表董事工作完成后，公司第八届董事会中兼任公司 高级管理人员以及由职工代表担任的董事人数总计未超过公司董事总数的二分 之一。 浙江九洲药业股份有限公司 关于非独立董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、非独立董事辞职情况 浙江九洲药业股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事 LI YUANQIANG 先生的辞职报告，因公司治理结构调整，LI YUANQIANG ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-065 浙江九洲药业股份有限公司 第八届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江九洲药业股份有限公司（以下简称"公司"）第八届董事会第十八次会议 于2025年 11 月12日以现场表决结合通讯表决的方式召开。本次董事会已于2025 年 11 月 7 日以电子邮件、电话等方式通知全体董事、高级管理人员。会议应出 席董事 9 人，实际出席董事 9 人。全体董事推举董事长花莉蓉女士主持本次会议， 本次会议参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关 规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于选举代表公司执行公司事务董事的议案》； 董事会同意选举花莉蓉女士（简历见附件）为代表公司执行公司事务的董事， 并担任公司法定代表人，任期自本次董事会审议通过之日起至公司第八届董事会 任期届满之日止。 表决结果：同意：9 票；反对：0 票；弃权：0 票。 2、审议通过了《关于选举审计委 ...

Group 1 - The core point of the article is that Jiuzhou Pharmaceutical (SH 603456) held its 18th meeting of the 8th board of directors on November 12, 2025, to discuss various proposals, including the election of a director to represent the company in executing its affairs [1] - For the fiscal year 2024, Jiuzhou Pharmaceutical's revenue composition is heavily weighted towards the production and sales of chemical raw materials and intermediates, which account for 98.56% of total revenue, while other businesses contribute only 1.44% [1] - As of the time of reporting, Jiuzhou Pharmaceutical has a market capitalization of 17.7 billion yuan [1]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has shown significant performance, with a year-to-date increase of 53.80%, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the period from January to September 2025, Jiuzhou Pharmaceutical achieved a revenue of 4.16 billion yuan, representing a year-on-year growth of 4.92%. The net profit attributable to shareholders was 748 million yuan, reflecting an 18.51% increase compared to the previous year [2]. - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the last three years [3]. Stock Market Activity - As of November 12, Jiuzhou Pharmaceutical's stock price was 20.28 yuan per share, with a trading volume of 283 million yuan and a turnover rate of 1.59%. The total market capitalization stood at 18.038 billion yuan [1]. - The stock has seen a net inflow of 10.22 million yuan from major funds, with significant buying activity noted in large orders [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 59,200, a rise of 10.22%. The average number of circulating shares per shareholder decreased by 9.27% to 15,035 shares [2][3]. - Notable institutional shareholders include Hong Kong Central Clearing Limited and China Europe Medical Health Mixed A, both of which increased their holdings [3].

Core Viewpoint - The article discusses the retirement of Huaxuan De, the former richest person in Taizhou, who plans to transfer his shares in Zhongbei Group and Taizhou GeDe to his daughters, marking a significant change in the ownership structure of Jiuzhou Pharmaceutical. Group 1: Share Transfer Details - Huaxuan De intends to transfer 42.50% of his shares in Zhongbei Group and 10% in Taizhou GeDe to his daughters, Huali Rong and Huaxiao Hui [1][2] - The share transfer includes 28.50% to Huali Rong and 14% to Huaxiao Hui, with the payment amounts being 41.33 million yuan and 20.48 million yuan respectively [1] - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's stock price, is approximately 2.476 billion yuan [1] Group 2: Company Background and Leadership Changes - Jiuzhou Pharmaceutical was founded in 1998, evolving from a struggling company to a prominent player in the pharmaceutical industry under Huaxuan De's leadership [3] - Huali Rong currently serves as the chairman of Jiuzhou Pharmaceutical, while Huaxiao Hui has resigned from her director position as of December 2024 [3][4] - Huaxuan De has been instrumental in the company's growth, transitioning it from raw material production to contract research and manufacturing [3] Group 3: Market Context and Implications - The transfer of shares signifies Huaxuan De's complete withdrawal from active management, potentially reducing distractions from the company's operations [7] - The recent legal issues surrounding Xu Xiren, a figure connected to Huaxuan De, have brought renewed attention to his legacy and the companies involved [5][6]

Core Viewpoint - The transfer of shares from Hua Xuande to his daughters marks a significant change in the ownership structure of Zhongbei Group and its indirect control over Jiuzhou Pharmaceutical, with the daughters becoming the new actual controllers of the company [1][2]. Group 1: Share Transfer Details - Hua Xuande plans to transfer 42.50% of his shares in Zhongbei Group and 10% in Taizhou Gede to his daughters, Hua Lirong and Hua Xiaohui, with payments of 41.33 million yuan and 20.48 million yuan respectively [1]. - The transferred shares correspond to an estimated market value of approximately 2.476 billion yuan in Jiuzhou Pharmaceutical [1]. Group 2: Impact on Company Control - Following the share transfer, Hua Xuande will no longer hold any shares in Zhongbei Group or Taizhou Gede, thus ceasing to have indirect control over Jiuzhou Pharmaceutical [2]. - The new actual controllers of Jiuzhou Pharmaceutical will be Hua Lirong, who is currently the chairman, and Hua Xiaohui, who has resigned from her director position [2]. Group 3: Hua Xuande's Contributions - Hua Xuande has significantly contributed to the development of Zhongbei Group and Jiuzhou Pharmaceutical, transforming the company from a struggling entity into a prominent player in the industry [2]. - Under his leadership, Jiuzhou Pharmaceutical was established in 1998 and went public in 2014, marking a pivotal moment in the company's history [2]. Group 4: Recent Developments - Hua Xuande remains the chairman of Zhongbei Group and holds director positions in other companies, despite stepping back from direct involvement in Jiuzhou Pharmaceutical [3]. - Recent news regarding the criminal detention of a related figure in the industry has brought Hua Xuande back into the spotlight, highlighting his connections within the sector [4].

证券代码：603456 证券简称：九洲药业 公告编号：2025-064 关于控股股东及一致行动人上层股权结构进行内部调整 暨实际控制人减少的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次股权比例调整的具体情况 截至本公告披露日，中贝集团持有公司 283,518,812 股股份，占公司总股本的 31.88%，为公司控股股东；中贝集团持有台州歌德 90.00%股权，台州歌德为中贝集 团的控股子公司，台州歌德持有公司 40,585,680 股股份，占公司总股本的 4.56%，为 公司控股股东的一致行动人。 本次调整前，花轩德分别直接持有中贝集团 42.50%股权、台州歌德 10.00%股权， 通过中贝集团和台州歌德合计间接持有公司 15.75%股权；花莉蓉分别直接持有中贝 集团 22.50%股权、九洲药业 3.59%股权，通过中贝集团间接持股、九洲药业直接持 股方式，合计持有公司 11.68%股权；花晓慧直接持有中贝集团 22.50%股权，通过中 贝集团间接持有公司 8.10%股权。 本次股权比 ...